- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06244953
Timely Interventions to Enable and Reach Patients With Heart Failure, and Their Caregivers With Palliative Care (TIER-HF-PC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Timely Interventions to Enable and Reach patients with Heart Failure, and their caregivers with Palliative Care, or TIER-HF-PC, is a novel model of palliative care, designed to address gaps of palliative care delivery for patients with advanced heart failure, and their caregivers.
TIER-HF-PC is a service, led by a palliative care nurse, with support by a palliative care physician. This nurse will actively screen and monitor patients for problems, and then match the type and intensity of palliative care treatments to the severity of problems reported. The nurse will also facilitate processes for patients to initiate contact with health care providers should problems arise. This decreases the overall burden on palliative care services, enabling a scalable and more cost-effective model of care for a larger number of patients. The service will also utilize a proactive approach to care, increasing self-care skills and understanding of disease and treatment options. Earlier palliative care support will enable problems to be managed actively before they escalate into crises.
Overall aim: To test the effectiveness and implementation of the interacting components of TIER-HF-PC.
Specific aim 1a: To evaluate the impact of TIER-HF-PC on patients. The primary outcome is patient quality-of-life at 24 weeks, measured on the Kansas City Cardiomyopathy Questionnaire. Secondary outcomes include patient anxiety, depression, coping, spirituality, healthcare utilization, survival, and cost-effectiveness of TIER-HF-PC.
Specific aim 1b: To evaluate the impact of TIER-HF-PC on caregivers. Outcomes evaluated include caregiver quality-of-life.
- Hypothesis 1: The researchers hypothesize that TIER-HF-PC will be superior to usual care, in improving patient and caregiver quality-of-life.
Specific aim 2: To evaluate the implementation outcomes of TIER-HF-PC.
- Hypothesis 2: The researchers hypothesize that participants will be satisfied with the TIER-HF-PC service, though modifications might be needed for fine-tuning of the appropriateness and timeliness of care provision in TIER-HF-PC. They will evaluate these implementation outcomes through a validated service evaluation survey and semi-structured interviews. Fidelity to study protocols will be assessed through audits of case notes and study processes.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dr Shirlyn Neo, MBBS, MRCP (UK), MMed, FAMS
- Phone Number: +65 63065838
- Email: shirlyn.neo.h.s@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore, 169609
- National Heart Centre Singapore
-
Contact:
- Dr David KL Sim, MBBS, MMed, MRCP(UK)
- Phone Number: +6567048895
- Email: david.sim@singhealth.com.sg
-
Singapore, Singapore, 768828
- Khoo Teck Puat Hospital
-
Contact:
- Dr Laurence LC Tan, MBBS, MMed, FAMS
- Email: tan.laurence.lc@ktph.com.sg
-
Singapore, Singapore
- National Cancer Centre, Singapore
-
Contact:
- Dr Shirlyn Neo, MBBS, MRCP (UK), MMed, FAMS
- Phone Number: +6563065838
- Email: shirlyn.neo.h.s@singhealth.com.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients:
- 21 years or older and
- able to communicate in English or Chinese and
- be of stage C or D heart failure, as defined by American College of Cardiology/American Heart Association (ACC/AHA) classification system and
- have functional limitation of New York Heart Association (NYHA) functional status of at least 2 or more and
- be deemed by their cardiologist's clinical judgement to have an expected prognosis of at least 6 months survival, and
- have had a heart failure related hospitalization event (e.g. symptomatic decompensated heart failure) within 6 months prior to recruitment and
- have a phone that allows telecommunication.
Caregivers must meet all the following inclusion criteria to be eligible for the study :
- direct, unpaid, family caregiver of the patient;
- self-reported by the patient to be the main person to be either:
- responsible for up to 4 hours a day of caregiving tasks
- and/or decision maker/spokesperson with the medical team
- Caregiver may or may not live in the same residence as the patient.
- Caregivers must be 21 years and above.
- Able to communicate in English or Chinese.
Exclusion Criteria:
Patients:
- have cognitive impairment (e.g., dementia)
- have severe, untreated, active mental illness (e.g., major depressive disorder)
- have ventricular assist device implant.
- have non-reversible hearing or visual loss or
- are active drug abuser or
- already known to a palliative care service.
Caregivers who meet any of the exclusion criteria at baseline will be ineligible for the study:
- have cognitive impairment (e.g., dementia) or
- have severe, untreated, active mental illness (e.g., major depressive disorder)
- have non-reversible hearing or visual loss.
- are active drug abuser or
- are a domestic helper for the patient
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Regular screening with needs-guided palliative care treatments
The patient continues to receive clinical care from the cardiologist, as well as palliative care treatments that are based upon his/her reported distress and concerns.
|
The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
|
Other: Usual Care
Patient is referred by cardiologist to palliative care.
|
Patient continues on clinical care by his/her cardiologist.
If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient quality of life (QOL)
Time Frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Patient quality of life will be measured at baseline, and again at 8 weeks, 16 weeks, and 24 weeks using KCCQ-12. Descriptive statistics, and measures of effect size will be used to compare the study groups at baseline, 8 weeks, 16 weeks, and 24 weeks. Longitudinal data analyses will be conducted to examine intervention effects using linear mixed-effects-modelling for repeated measures at baseline, 8 through 16 and 24 weeks, constraining the baseline mean to be equal between intervention and control groups with indicators for time, group, and time by group interactions. Estimate of standard deviation of residuals from the mixed-effects model will be used to compute effect size (Cohen's d) to estimate the efficacy. The minimum score on KCCQ is 0 and maximum possible score is 100. A higher score indicates a better quality of life. |
Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of TIER-HF-PC from patient and caregiver participants - through completion of the client satisfaction questionnaire (CSQ-4)
Time Frame: Up to 48 weeks.
|
The total score of the CSQ-4 will be calculated for each participant. For the assessment of acceptability, scores from participants from both intervention and control groups will be pooled. The minimum expected score per participant is 4, and the maximum expected score per participant is 16. A higher score indicates higher satisfaction. The percentage of participants in TIER-HF-PC who have at least a CSQ score of 12 and above will also be calculated. |
Up to 48 weeks.
|
Patient anxiety and depression
Time Frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Patient anxiety will be tracked at baseline, 8 weeks, 16 weeks, and 24 weeks, using the hospital anxiety and depression scale (HADS).
Descriptive statistics and measures of effect size will be used to compare the study groups at baseline, 8 weeks, 16 weeks and 24 weeks.
Longitudinal data analyses will be conducted to examine intervention effects using linear mixed-effects-modelling for repeated measures at baseline, 8 through 16 and 24 weeks, constraining the baseline mean to be equal between intervention and control groups with indicators for time, group, and time by group interactions.
Estimate of standard deviation of residuals from the mixed-effects model will be used to compute effect size (Cohen's d) to estimate the efficacy.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Patient Spirituality
Time Frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Patient spirituality will be tracked at baseline, 8 weeks, 16 weeks and 24 weeks, using the Functional Assessment of Chronic Illness Therapy Spiritual Well-Being Scale (FACIT-Sp-12).
Descriptive statistics and measures of effect size will be used to compare the study groups at baseline, 8 weeks, 16 weeks and 24 weeks.
Longitudinal data analyses will be conducted to examine intervention effects using linear mixed-effects-modelling for repeated measures at baseline, 8 through 16 and 24 weeks, constraining the baseline mean to be equal between intervention and control groups with indicators for time, group, and time by group interactions.
Estimate of standard deviation of residuals from the mixed-effects model will be used to compute effect size (Cohen's d) to estimate the efficacy.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Caregiver Quality of Life
Time Frame: Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
The change in caregiver quality of life (QOL) at 8 weeks, 16 weeks, and 24 weeks as compared to baseline will be evaluated.
The outcome measure used is the Singapore Caregiver Quality of Life Scale (SCQOLS-15).
Descriptive statistics and measures of effect size will be used to compare the study groups at baseline, 8 weeks, 16 weeks and 24 weeks.
Longitudinal data analyses will be conducted to examine intervention effects using linear mixed-effects-modelling for repeated measures at baseline, 8 through 16 and 24 weeks, constraining the baseline mean to be equal between intervention and control groups with indicators for time, group, and time by group interactions.
Estimate of standard deviation of residuals from the mixed-effects model will be used to compute effect size (Cohen's d) to estimate the efficacy.
|
Baseline, 8 weeks, 16 weeks, and 24 weeks.
|
Assessment of impact of TIER-HF-PC on healthcare utilization
Time Frame: Up to 24 weeks.
|
|
Up to 24 weeks.
|
Healthcare cost analysis
Time Frame: Up to 24 weeks.
|
The total cost of inpatient bills and outpatient bills including emergency visit bills for TIER-HF-PC participants and usual care participants from week 1 to week 24 will be summed up to quantify the cost differences between both groups by generalized linear model with Gamma model and robust standard error.
|
Up to 24 weeks.
|
Survival analysis
Time Frame: Up to 48 weeks.
|
The differences in survival between TIER-HF-PC and usual care will be analyzed using a Cox model regression, censoring at week 48 or death, whichever occurs earlier.
|
Up to 48 weeks.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dr Shirlyn Neo, MBBS, MRCP (UK), MMed, FAMS, National Cancer Centre, Singapore
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TIER-HF-PC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on TIER-HF-PC
-
University of Alabama at BirminghamUS Department of Veterans AffairsCompletedHeart FailureUnited States
-
Contra Costa Health ServicesUnknownSocial Determinants of HealthUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Nursing Research (NINR)RecruitingAdvanced Heart Failure | Advanced Lung Cancer | Advanced Non-colorectal Gastro-intestinal CancerUnited States
-
Loma Linda UniversityRecruiting
-
CHU de Quebec-Universite LavalUniversity of British Columbia; McGill University; Canadian Institutes of Health... and other collaboratorsActive, not recruitingAneuploidy | Prenatal DisorderCanada
-
University School of Physical Education in WroclawIRCCS San Camillo, Venezia, Italy; National Center for Research and Development... and other collaboratorsCompletedDepression | StrokeItaly, Poland
-
Population Health Research InstituteMcMaster University; Hamilton Health Sciences CorporationRecruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaUnknownEnd Stage Renal DiseaseSpain, France, Italy, Belgium
-
The University of Hong KongHospital Authority, Hong KongActive, not recruitingHeart Failure | Telerehabilitation | Self Care | Empowerment | Disease ManagementHong Kong
-
VA Office of Research and DevelopmentCompleted